Vault Development Cloud brings together applications for clinical,
quality, and regulatory to streamline end-to-end product development
processes
PHILADELPHIA--(BUSINESS WIRE)--
2017 Veeva Global R&D Summit — Veeva
Systems (NYSE: VEEV) today announced that Veeva Vault Development
Cloud is gaining momentum as the technology
foundation for drug development in life sciences. Vault Development
Cloud delivers unified applications for clinical, regulatory, and
quality on the Veeva
Vault Platform to help organizations eliminate system, site, and
country silos throughout their drug development processes. More than 100
customers have adopted multiple applications across Vault Development
Cloud suites Vault
Clinical, Vault
Quality, and Vault
RIM to drive greater efficiency and maintain compliance throughout
the product lifecycle.
Healthcare leader Eli Lilly (NYSE: LLY) turned to Vault Development
Cloud to manage business processes, content, and data across its global
product development organization. The company expects to deploy Vault
Development Cloud applications to more than 80,000 users.
“Eli Lilly’s vision is to speed research and development from protocol
through submissions,” said Robert Nist, vice president and information
officer, medicines development and connected care IT at Eli Lilly.
“Vault Development Cloud gives us next-generation cloud applications to
drive end-to-end business processes more efficiently and get medicines
to patients much faster.”
Biopharmaceutical company TESARO implemented Vault Development Cloud
applications Vault
eTMF, Vault
QMS, and Vault
Submissions to bring together business processes in clinical,
quality, and regulatory on one platform as it develops new cancer
therapies.
“The technology we use needs to increase speed and improve quality as we
work to provide transformative therapies to people bravely facing
cancer,” said Brian Blood, vice president, IT at TESARO. “Adopting Vault
Development Cloud across clinical, quality, and regulatory operations
enabled our teams to be more efficient and get time back to focus on
higher value tasks that serve our mission.”
Aeglea BioTherapeutics implemented Vault Development Cloud applications
for its teams who are developing engineered human enzymes to address
unmet medical needs in rare genetic disease and cancer. Vault
Development Cloud helps Aeglea increase productivity and efficiency
throughout its product development efforts.
“As a rapidly growing company with multiple development programs in the
pipeline, we needed to implement the right platform from the outset,”
said Tom Wilson, senior director of quality assurance at Aeglea. “Vault
Development Cloud enabled fast user uptake for our product development
teams and required the least amount of IT involvement.”
“There’s a significant opportunity for life sciences organizations to
increase operational efficiency across drug development,” said Jennifer
Goldsmith, senior vice president, Veeva Vault at Veeva. “Vault
Development Cloud gives customers the technology foundation to break
down barriers throughout clinical, regulatory, and quality and
streamline their end-to-end product development processes.”
Veeva also announced today that Veeva
Vault CTMS is gaining momentum with customers needing to unify
clinical information and processes across their studies, and that more
customers are modernizing quality and content management in the cloud
with Vault Quality. Read the Vault
CTMS news and the Vault
Quality news to learn more.
Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veevasystems on Twitter: twitter.com/veevasystems
Like
Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 550 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended July 31, 2017. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
® 2017 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo
are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other
registered and unregistered trademarks.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171003006419/en/
Source: Veeva Systems Inc.